RecruitingPhase 4NCT07308574
Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS
Studying Atypical hemolytic uremic syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Intervention
- Ravulizumab(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (12)
- Research Site, Bunkyō City, Japan
- Research Site, Hirakata-shi, Japan
- Research Site, Iruma-Gun, Japan
- Research Site, Kyoto, Japan
- Research Site, Matsumoto-shi, Japan
- Research Site, Miyazaki, Japan
- Research Site, Nagoya, Japan
- Research Site, Nara, Japan
- Research Site, Nerima-ku, Japan
- Research Site, Sapporo, Japan
- Research Site, Shinjuku-ku, Japan
- Research Site, Tsu, Japan
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07308574 on ClinicalTrials.govOther trials for Atypical hemolytic uremic syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07218536The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in EgyptAstraZeneca
- RECRUITINGPHASE3NCT05935215Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)Novartis Pharmaceuticals
- ACTIVE NOT RECRUITINGNCT06099236A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Atypical Hemolytic Uremic Syndrome PatientsAstraZeneca
- ACTIVE NOT RECRUITINGNANCT05985122New Analytic Tools for aHUS and C3G DiagnosisMario Negri Institute for Pharmacological Research
- RECRUITINGNANCT05805202Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized TherapyMario Negri Institute for Pharmacological Research
- ACTIVE NOT RECRUITINGPHASE3NCT04958265A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)Hoffmann-La Roche
- ACTIVE NOT RECRUITINGPHASE3NCT04861259A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)Hoffmann-La Roche
- RECRUITINGNCT04745195Complement Prospective Evaluation of Thrombotic Microangiopathy on EndotheliumMaastricht University Medical Center